ArticleAmerican journal of cancer research2026
Serum total bile acid correlates with macrophage-related immune features in colorectal cancer patients after cholecystectomy.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholecystectomy has been associated with an elevated risk of colorectal cancer (CRC), potentially mediated by alterations in bile acid metabolism. This single-center retrospective case-control study aimed to investigate the clinical significance of serum total bile acid (TBA) levels in patients with CRC after cholecystectomy, their association with farnesoid X receptor (FXR) expression, and their relationship with tumour-associated macrophage (TAM)-related immune features within the tumour microenvironment. A total of 216 post-cholecystectomy patients with CRC and 209 post-cholecystectomy controls without CRC were enrolled in the study. Serum TBA levels were quantified and statistically compared between the two groups. Immunohistochemical analysis was performed on tumour tissues to assess FXR expression and TAM markers (CD163, CD68). Pearson correlation analysis was performed to examine the associations among serum TBA levels, FXR expression, and TAM-related immune features. Serum TBA levels were significantly higher in the CRC group (8.74 ± 4.45 µmol/L) compared to the Control group (4.61 ± 2.90 µmol/L). ROC analysis showed an AUC of 0.79 (95% CI: 0.74-0.83). Elevated TBA levels were associated with advanced disease features, including higher TNM stage and lymph node metastasis. Immunohistochemistry revealed increased FXR expression and a higher proportion of CD163
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.